Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 3, 2010

Atlas Biolabs Joins Roche NimbleGen’s Certified Service Provider Program for Targeted Enrichment

  • Roche NimbleGen reports that Atlas Biolabs, a Berlin-based company, has officially become a certified service provider for NimbleGen Sequence Capture. It will provide services for NimbleGen 454 optimized sequence capture arrays, coupled with sequencing services on the Genome Sequencer FLX System from 454 Life Sciences, a Roche company.

    Atlas Biolabs will process customer gDNA samples for genomic enrichment, using the complete NimbleGen sequence capture workflow optimized for 454 GS FLX Titanium Series sequencing using 385K arrays (capture of up to 5 Mb custom regions) and 2.1M arrays (human exome and capture of up to 30 Mb custom regions).



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »